Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of BI 474121 in Healthy Young and Elderly Subjects
NCT04537897Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 474121 in schizophrenia and Alzheimer's disease (AD) (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 21 days. Started Oct 2020; status: completed.
02
Drugs
BI 474121
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04537897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537897.